Galapagos FIRST LOOK: Presents positive updated CAR-T results in r/r NHL at EHA
Galapagos presented updated results from the phase 1/2 (ATLANTA-1) trial of GLPG5101 (CD19 CAR-T) in r/r NHL (non-Hodgkin's lymphoma) at EHA, which continue to show solid outcomes in line with Yescarta (CD19 CAR-T, Gilead), while the FL cohort stands out for its high CR rate. With >30 patients, the dataset is beginning to mature, de-risking the CAR-T program in r/r NHL, and we look forward to IND submission in the US in mid-2024 to unlock the next stage of development. We reiterate our € 50 TP and BUY rating.Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, addressing disease areas of high unmet medical need. Execution on its proprietary drug target discovery platform has delivered a pipeline that consists of three Phase 2, three Phase 1, five pre-clinical, and 20 discovery programs in inflammation, cystic fibrosis, or CF, osteoarthritis, and other indications. Co.'s highly flexible platform offers applicability across a broad set of therapeutic areas. Co.'s programs include filgotinib, GLPG1837, GLPG1690, GLPG2222, GLPG1972.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.